Aclaris Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Aclaris Therapeutics

28/07/2023 15:43

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 1
(estimated). 
    * The Wayne Pennsylvania-based  company is expected to
report  a
24.3% increase in revenue to $1.899 million from $1.53 million a
year ago, according to the mean estimate from 9 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aclaris
Therapeutics Inc
is for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $29.5​, above​ its last closing price
of $9.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6
 Dec. 31 2023  -0.45       -0.45      -0.41     Beat    8
 Sep. 30 2022  -0.39       -0.40      -0.30     Beat    24.2​
 Jun. 30 2022  -0.36       -0.36      -0.31     Beat    13.5
 ​​Mar.        -0.40       -0.40      -0.31     Beat    23.1
 31 2022                                                
 Dec. 31 2021  -0.37       -0.36      -0.37     Missed  -1.4​
 Sep. 30 2021  -0.29       -0.28      -0.35     Missed  -25
 Jun. 30 2021  -0.27       -0.28      -0.34     Missed  -22.9
 This summary was machine generated July 28 at 14:43 GMT.  All
figures in US dollars  unless otherwise stated